A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

Recruiting now · Phase 2

Conditions studied: Myeloma, Myeloma Multiple

In brief

This study is to see if the standard of care subcutaneous injection of bortezomib can safely be administered at home by the patient or caregiver. All tests and assessments are based on standard of care procedures.

Key facts

Study ID

NCT04268199

Run by

AHS Cancer Control Alberta

People needed

100

Starts

2020-05-29

Expected to finish

2026-12-01

Last updated by the study team

2025-12-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients are aged 18 years old or older with a diagnosis of symptomatic myeloma,
• Stable clinical status as deemed by responsible investigator,
• Personally (or caregiver) willing and deemed capable to self-administer with teaching,
• Previously received more than 4 injections of bortezomib within the hospital and/or cancer centre environment,
• Signed informed consent.

You may not qualify if…

• Currently participating in clinical trials that includes the use of bortezomib,
• History of allergic reactions to bortezomib,
• History of bleeding attributable to bortezomib,
• History of greater than or equal to grade 3 side effects attributable to bortezomib,
• Clinically deemed unlikely to be compliant with therapy by responsible investigator,
• Life expectancy anticipated to be less than 6 months,
• Deemed geographically inaccessible to receive care.

Where it is running

• Arthur J.E. Child Comprehensive Cancer Centre — Calgary, Alberta, Canada (enrolling)
• Cross Cancer Institute — Edmonton, Alberta, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.